Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2022-01-20 Regulatory Filings
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
신규시설투자등(자율공시)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Cha Biotech regarding a 'New Facility Investment' (CDMO GMP facility). It details the investment amount, purpose, duration, and board approval, which constitutes a capital expenditure announcement. Since it does not fit into specific categories like M&A or share issuance, and is a formal regulatory disclosure of a material corporate event, it is classified as a Regulatory Filing (RNS).
2022-01-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status of a major shareholder (Cha Kwang-yul) and his special related parties in the company 'Cha Biotech'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-01-04 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the share ownership, changes in holdings (specifically '장내 매수' or open market purchases), and the relationship between the reporter and special related parties. This falls under the category of Major Shareholding Notification.
2021-12-28 Korean
전환가액의조정(제6회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (제6회차 전환사채). It details the change in conversion price due to market price fluctuations, the resulting change in the number of convertible shares, and the legal basis for the adjustment. This type of disclosure is a standard capital structure update related to financing instruments, which falls under the 'Capital/Financing Update' category.
2021-12-20 Korean
신주인수권행사가액의조정(제7회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from Cha Biotech regarding the adjustment of the exercise price of stock warrants (신주인수권행사가액의 조정). This type of filing relates to changes in capital structure and potential future share issuance resulting from warrant exercises. According to the provided definitions, announcements regarding capital changes, including adjustments to warrant exercise prices, fall under the 'Share Issue/Capital Change' category.
2021-12-20 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or the meeting results, but rather serves as a formal regulatory notice of the procedural steps for the meeting. Given the nature of the announcement as a regulatory disclosure, it fits best under the RNS category.
2021-12-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.